title: Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study.
abstract: BACKGROUND
  Long-term randomized trials comparing asthma outcomes between inhaled corticosteroids in real-world populations are lacking. As such, rigorously conducted observational studies to complement the findings of randomized trials are needed.
  
  
  OBJECTIVE
  We sought to compare asthma-related outcomes over 1 year as recorded in a large primary care database for patients aged 5 to 60 years receiving a first prescription (initiation population) or dose increase (step-up population) of hydrofluoroalkane (HFA)-beclomethasone or fluticasone.
  
  
  METHODS
  We used a retrospective matched cohort study in which patients were matched on baseline demographic and disease severity measures. Coprimary outcomes were asthma control (a composite measure comprising no unplanned visit or hospitalization for asthma, oral corticosteroids, or antibiotics for lower respiratory tract infection) and exacerbation rate.
  
  
  RESULTS
  More than 80% of patients in each population achieved asthma control; 10% and 16% of patients in the initiation and step-up populations, respectively, received add-on or combination therapy during the year. Fluticasone was prescribed at significantly higher doses than HFA-beclomethasone for both populations (P <or= .001). In the initiation population (n = 1319 in each cohort) the adjusted odds ratio for achieving asthma control with HFA-beclomethasone was 1.30 (95% CI, 1.02-1.65) relative to fluticasone. In the step-up population (cohorts: n = 250) the adjusted odds ratio for achieving asthma control with HFA-beclomethasone was 1.22 (95% CI, 0.66-2.26). Exacerbation rates were similar between cohorts.
  
  
  CONCLUSIONS
  In a real-world setting patients receiving HFA-beclomethasone had a similar or better chance of achieving asthma control at lower prescribed doses than with fluticasone.
authors.affiliation: Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom.
authors.forename: David
authors.initials: D
authors.lastname: Price
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Martin
authors.forename: Neil
authors.initials: N
authors.lastname: Barnes
authors.forename: Paul
authors.initials: P
authors.lastname: Dorinsky
authors.forename: Elliot
authors.initials: E
authors.lastname: Israel
authors.forename: Nicolas
authors.initials: N
authors.lastname: Roche
authors.forename: Alison
authors.initials: A
authors.lastname: Chisholm
authors.forename: Elizabeth V
authors.initials: EV
authors.lastname: Hillyer
authors.forename: Linda
authors.initials: L
authors.lastname: Kemp
authors.forename: Amanda J
authors.initials: AJ
authors.lastname: Lee
authors.forename: Julie
authors.initials: J
authors.lastname: von Ziegenweidt
authors.forename: Gene
authors.initials: G
authors.lastname: Colice
mesh_terms: D000293:Adolescent; D000328:Adult; D000730:Androstadienes / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000068298:Fluticasone; D001507:Beclomethasone